

June 29, 2018

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Tatsuro Kosaka
Inquiries to: Masahiko Uchida, General Manager,
Corporate Communications Dept.
Tel: +81-(0)3-3273-0881

Announcement of an Appeal against Chugai in Patent Infringement Lawsuit

Chugai Pharmaceutical Co., Ltd. announced today that it received a petition of appeal from the Intellectual Property High Court. The appeal was filed by Baxalta as of May 10, 2018, against the following judgment rendered by the Tokyo District Court on March 28, 2018.

1. History

Judgment (Favorable ruling for Chugai)	March 28, 2018
Service of appeal	June 29, 2018

2. Background for the Action

In the original trial, it was alleged by Baxalta that Chugai's drug for treatment of hemophilia A, HEMLIBRA[®] (generic name: emicizumab), infringed Baxalta's patent (patent number 4313531) and thus it filed for an injunction against manufacture, usage, transfer, exportation, and offer of any transfer regarding HEMLIBRA, and requested cessation. With regard to this action, Tokyo District Court rendered a decision in favor of Chugai's claim. Given this ruling, Baxalta appealed to the Intellectual Property High Court.

3. Party Who Filed the Appeal

(1) Name:	Baxalta Incorporated Baxalta GmbH
(2) Address:	1200 Lakeside Drive Bannockburn, IL 60015, USA Thurganerstrasse 130 Glattpark Opfikon 8152, Switzerland

4. Prospects

Chugai is confident that HEMLIBRA does not infringe Baxalta's patent as so rendered by the District Court, and intends to continue pursuing its defense at the appellate court. Therefore no changes are expected in Chugai's financial prospects.

Trademarks used or mentioned in this release are protected by law.

###